Measuring apolipoprotein B (apoB) is more effective than traditional LDL or non-HDL cholesterol testing for identifying patients who require intensive therapy to prevent heart attacks and strokes, according to a study published in the journal JAMA.
Why ApoB Provides a More Accurate Risk Profile
Standard lipid panels focus on LDL (low-density lipoprotein) and non-HDL cholesterol. While these metrics have long served as the primary clinical markers for cardiovascular risk, they do not account for the total number of harmful particles in the bloodstream.
"Research strongly shows that apolipoprotein B (apoB) is better at identifying who is at risk, because it counts the total number of harmful particles in the blood," said Dr. Ciaran Kohli-Lynch, assistant professor of preventive medicine at Northwestern University Feinberg School of Medicine.
Because apoB measures the number of cholesterol carrying particles, it provides a more direct indicator of cardiovascular risk. These particles can become trapped inside artery walls, where they build up into plaques that restrict blood flow, eventually causing cardiovascular events.
Comparing Testing Strategies
To determine the clinical and economic value of shifting testing protocols, researchers developed a computer simulation representing 250,000 U.S. adults eligible for statin therapy who had not yet developed cardiovascular disease. The model compared three distinct treatment-guidance strategies:
- LDL Cholesterol: Setting a goal of less than 100 mg/dL.
- Non-HDL Cholesterol: Setting a goal of less than 118 mg/dL.
- ApoB: Setting a goal of less than 78.7 mg/dL.
When patients failed to reach their respective targets in the simulation, the model intensified treatment, starting with stronger statins and progressing to the addition of ezetimibe if necessary. The results indicated that the apoB-guided approach consistently prevented more heart attacks and strokes over a patient’s lifetime compared to the other two methods.
Clinical Implications for Future Guidelines
The study, "Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy," arrives as medical organizations continue to refine cardiovascular prevention strategies. Earlier this year, the American Heart Association and 10 other organizations updated their guidelines, recommending that more individuals begin cholesterol-lowering therapy at younger ages.
"We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. healthcare payers," said Kohli-Lynch.
Despite these findings, apoB is not yet a standard component of routine care. The primary barrier remains the logistical and financial burden of an additional blood test. However, as the medical community seeks to optimize preventative care, the study suggests that the increased accuracy of apoB testing justifies its implementation in clinical practice.
Key Considerations for Patients
- Direct Particle Count: ApoB measures the number of cholesterol carrying particles that can contribute to plaque buildup, whereas LDL and non-HDL cholesterol do not fully capture a person’s cardiovascular risk.
- Cost-Effectiveness: The study suggests that while apoB testing may involve an extra blood draw, the long-term savings from prevented cardiac events make it a sound economic choice for the healthcare system.
- Guideline Updates: With recent shifts toward earlier medical intervention for cholesterol, accurate risk assessment is increasingly critical for primary prevention.
The research was supported by the American Heart Association Career Development Award 24CDA1274989. Coauthors of the study include Dr. John Wikins and Dr. Samuel Luebbe.